Pegfilgrastim biosimilar(Lupin Ltd.)

Emerging economies across the Asia-Pacific and Africa are expected to emerge as key investment destinations for key giants Fact.MR, Rockville MD: Fact.MR’s generic injectables market report forecasts a relatively stable outlook for 2021, majorly fueled by accelerating regulatory approvals to initiate clinical trials for developing possible drug candidates to eradicate the novel coronavirus pandemic. Recessionary downturns were avoided significantly through 2020, as candidates were endowed with priority approval status by regulatory authorities. Future growth prospects are heavily reliant on accrued historical gains arising out of high import dependence from key manufacturing hubs. India is anticipated to reap the maximum benefits, as generic drugs contribute greater than 70% of the total pharmaceutical industry revenue. As of now, a total of 19 active pharmaceutical ingredient (API) applications have been approved under the Production Linked Incentive (PLI) Scheme to promote domestic manufacturing of Key Starting Materials (KSMs) at a cost of US$ 636 million. According to Fact.MR’s projections, the market is expected to cross US$ 1 billion by the middle of this decade, a significant chunk of which is anticipated to be yielded from accelerated development of anti-retroviral drugs. In November 2020, for instance, a coalition of 18 pharmaceutical companies across India, Bangladesh, China and South Africa- the four key emerging economies- specializing in generic drugs are expected to bolster drug development prospects for the SARS CoV2. The collaboration includes Sun Pharma, Lupin, Heterco, Natco, Strides Shasun, Aurobindo and Zydus Cadila. “Prominent generic injectables manufacturers are taking advantage of increasing government approvals for biosimilar candidates to accelerate treatment of several chronic and infectious conditions, prompting a flurry of clinical trials and product launches, providing stimulus to market growth,” says the Fact.MR analyst. Request a report sample with 170 pages to gain comprehensive insights at Key Takeaways from Fact.MR’s Generic Injectables Study Large molecular generic injectables to garner a highly lucrative market share By container, prefilled syringes to experience maximum sales, fueled by growing demand for precision medicine Oncology biosimilars development gaining traction, infectious disease treatment injectables experiencing similar incline Deepening presence of prominent pharmaceutical giants widening US growth prospects Broad savings margins of nearly 90% to uplift generic injectables growth prospects across the UK Germany and France to experience credible growth in the cardiology generic injectables domain India to be the most lucrative global market, attributed to its apex position in generic drugs production Generic Injectables Market- Prominent Drivers Growing demand for inexpensive alternatives to branded injectables is spurring generic injectables market growth An expanding orphan drugs landscape to bolster future development projects for new generic injectables Manufacturers are touting enhanced generic injectables production, attributed to their potential in yielding considerable cost savings Generic Injectables Market- Key Restraints Small-scale injectable manufacturers are experiencing expansion challenges, owing to their limited capacity to source expensive raw material Thinning profit margins due to reduced drug prices have shrunk revenue pools, restraining growth Discover more about the generic injectables market with 88 figures and 106 data tables, along with the table of contents. You will also find detailed market segmentation on Competitive Landscape Prominent generic injectables manufacturers profiled by Fact.MR include Pfizer Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., KGaA, Mylan NV, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Ltd., Sanofi and Biocon. Deployment of biosimilars forms the core marketing strategy of a majority of the aforementioned market players. In January 2020, Pfizer Inc. introduced three new oncology biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab- qyyp) across the United States. With these biosimilar launches, Pfizer became a debutant in the monoclonal antibody oncology treatment domain. Furthermore, in May 2020, the US FDA approved for review Fresenius Kabi’s Biologics License Application (BLA) for its MSB11455 pegfilgrastim biosimilar candidate for Neulasta®. This acceptance of review has provided oncologists with enhanced scope for improving cancer care across the country. Get Customization on this Report for Specific Research Solution More Valuable Insights on the Generic Injectables Market The research study on the global generic injectables market by Fact.MR incorporates an unbiased assessment of key factors and trends responsible for shaping the landscape of the global generic injectables market. Market statistics have been presented on the basis of Product (Large-molecule Injectables and Small-molecule Injectables), Container (Vials, Ampoules, Premixes, Prefilled Syringes and Others), Application (Oncology, Infectious diseases, Cardiology, Diabetes, Immunology and Others) and Route of Administration (Intravenous, Intramuscular, Subcutaneous and Others) across five major regions. Explore Fact.MR’s Coverage on the Healthcare Domain Earwax Removal Aid Market: Fact.MR’s study on the global earwax removal aid market provides detailed assessment on the key market dynamics, including drivers, trends, opportunities, restraints, and detailed information about the earwax removal aid market structure. Surgical Sutures Market: Fact.MR’s exclusive coverage on the surgical sutures market incorporates the latest and future trends shaping growth prospects across key segments and geographical locations. The report features unique and salient factors that will have a significant impact on the development of the surgical sutures market during the forecast period. Niacin and Niacinamide Market: A detailed assessment of niacin and niacinamide value chain analysis, business execution, and supply chain analysis across regional markets have been covered in Fact.MR’s exclusive coverage on the subject. Statistics about prominent segments across key geographies have also been included in this report. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583